A forensic aged-care analysis of why private-room choking events are harder to rescue: reduced visibility, call-light friction, room-level spatial constraints, and the dangerous seconds after an unsuccessful first manual maneuver.

A 2026 regulatory explainer showing why 'FDA registered' is not the same as FDA-authorized, what QXN and 21 CFR 874.5400 mean, and why authorized status reflects both legal identity and performance expectations after unsuccessful BLS.

An evidence-led Fitiger article explaining who is inside the FDA-authorized intended-use population for anti-choking devices, what the known risks are, and why safety depends on preserving first-line rescue before second-line suction use.

A Fitiger engineering and product safety team review of what the best current evidence actually shows about anti-choking devices. The article explains the difference between mechanical plausibility and clinical superiority, why FDA treats suction as second-line after unsuccessful BLS, and how simulation, case-series, cadaver, bench, and systematic-review evidence should be read in 2026.

A Fitiger engineering and product safety team guide to spotting unsafe counterfeit anti-choking devices in 2026. Covers QXN verification, De Novo status, one-way valve behavior, negative-pressure output, leakage margin, and why copied appearance can hide mechanical failure.

A technical Fitiger article explaining why seal quality can affect whether second-line suction becomes usable force or wasted delay. Covers 2026 FDA QXN framework, facial hair leakage, edentulous anatomy, pressure-loss mechanics, and the 5.4 kPa starch-bolus resistance threshold.

A Fitiger engineering and product safety team review of how to read anti-choking device evidence in 2026. Separates what cadaver studies, simulator trials, bench testing, and real-world case series can answer, and explains why FDA places suction devices only after unsuccessful first-line BLS.

A technical and regulatory Fitiger article explaining the difference between FDA registration, listing, and authorization for anti-choking devices in 2026. Covers QXN, 21 CFR 874.5400, the 2025 import alert, and why authorization is a performance-control signal as well as a legal status.

A practical Fitiger guide to placing a choking rescue device at home, in the car, or in travel gear without letting storage choices delay first-line rescue.

This article explains the mechanical logic behind second-line suction anti-choking devices: vent path, one-way valve function, negative pressure range measured negative pressure in published testing, mask seal integrity, may fail to resolve a choking emergency and may create additional risk and why counterfeit copies can fail or worsen an airway emergency.

The Fitiger FoldPumpVac™ is a compact, foldable, FDA-approved anti choking device that clears airway obstructions in about three seconds, enhancing traveler safety with portability and ease of use.

Fitiger FoldPumpVac is a compact anti-choking device for home readiness, designed as a portable choking rescue kit for second-line airway backup planning alongside first-aid guidance.

Fitiger FoldPumpVac is a compact choking rescue device home kit for family safety, built for portable second-line airway backup planning alongside first-aid readiness.